患者参加型癌化学療法 ... - yakushi.pharm.or.jp

1 Hon [100%]629a b c d e e-mail: khitochi ZASSHI126(8) 629 642 (2006) 2006 The Pharmaceutical Society of Japan Regular Articles ,a,d a e a a a b c c c d aMonitoring the Side E ects of Cancer Chemotherapy with Patients The Participation of Patients in Cancer Therapy and Sharing Patient Information Hitoshi KAWAZOE, ,a,dTomomi KUBO,aNaomi IIHARA,eChiaki DOI,aMakiko OKUJYOH,aNoriyasu FUKUOKA,aSatoshi FUJIMOTO,bNobuhiro KANAJI,cShuji BANDOH,cToshihiko ISHIDA,cYoshiharu TAKIGUCHI,dand Hitoshi HOUCHIaaDepartment of Pharmacy,bDepartment of Nursing,cFirst Department of Internal Medicine, KagawaUniversity Hospital, 1750 1 Ikenobe Miki-cho, Kita-gun, Kagawa 761 0793, Japan,dDepartment ofClinical Pharmacology.

2 Graduate School of Pharmaceutical Sciences, The University ofTokushima, 1 78 1 Sho-machi, Tokushima City 770 8505, Japan, andeFaculty ofPharmaceutical Sciences at Kagawa Campus, Tokushima Bunri University,1314 1 Shido, Sanuki City 769 2193, Japan(Received February 3, 2006; Accepted May 8, 2006; Published online May 12, 2006)The purpose of this study was to assess patient participation in cancer therapy and the sharing of patient informa-tion among the medical care team(physicians, nurses, pharmacists, and especially patients).Wemonitoredthesidee ects of cancer chemotherapy with patients, and developed two support tools: One scored the points of subjective symp-toms(fatigue, anorexia, nausea, etc)by patients, and the other recorded objective symptoms(clinical examinationdata)by pharmacists.

3 It is most important that they attend each patient at their bedside. At this time, the trial was eval-uated by questionnaire survey by inpatients receiving cancer chemotherapy(n 15). As a result, all patients(15/15)responded that this trial was necessary. This trial addressed the following: 1)increased communication between patientsand medical sta concerning side e ects(14/15),2)increased interest in side e ects(10/15),3)when a patient tellsmedical sta about side e ects, they act on it(10/15). None of the patients felt inconvenienced by scoring every day(0/15), or anxiety about side e ects(0/15). Furthermore, all patients(15/15)responded that ``participation of phar-macists in cancer chemotherapy'' was necessary. This trial revealed no problems and suggested that patients related tothe center of medical care.

4 We should be careful in interpreting results of this small sized trial; however, the followingconclusions should be reached: 1)introduction of monitoring side e ects of cancer chemotherapy with patients, 2)de-velop communication among the medical care words cancer chemotherapy; side e ects monitoring; patient participation; sharing patient information; medi-cal care team 1) 2) 2 9) 2,4 6,10,11) 5 9,12) hon [100%]630630 Vol.

5 126 (2006) 1 2 3 4 Quality of Life(QOL 1. 1-1.)

6 Microsoft Excel 2 1 A3 1 2 3 Monthly 1 28 6,8) 4 13 15) 5 5) 1-2. QOL Table 1 JCOG/JSCO 16) Grade 0 3 4 Grade 0 16) Grade 4, 5 Grade 5 Grade 4 Grade 16) Ta-ble 2 1-3.

7 3 1 WBC 47 87 100 /ml 2 NEU ( ) 3 hon [100%]631 Table 1. A Selection from Common Terminology Criteria for Adverse Events (CTCAE ) Japanese Translation Edition by Japan Clinical Oncology Group(JCOG)/JapanSociety of Clinical Oncology(JSCO) Grade 12345 ) / ) / /TPN 24 24 / /TPN / / )

8 / / / / / / / ) 4 / 4 6 / 24 7 / 24 ) 24 1 24 2 5 24 24 6 24 TPN ANC 109/L ) C C C 24 C 24 631No.

9 8hon [100%]632 Table 2. A ``Therapy Sheets'', the ``Side E ects Self-check Sheet'' 123456789 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 //////////////////////////// 3 33333333333333333333333333332 22222222222222222222222222221 11111111111111111111111111110 0000000000000000000000000000 3 33333333333333333333333333332 22222222222222222222222222221 11111111111111111111111111110 0000000000000000000000000000 3 33333333333333333333333333332 22222222222222222222222222221 11111111111111111111111111110

10 0000000000000000000000000000 3 33333333333333333333333333332 22222222222222222222222222221 11111111111111111111111111110 0000000000000000000000000000 3 33333333333333333333333333332 22222222222222222222222222221 11111111111111111111111111110 0000000000000000000000000000 ) ) 632 Vol.